Literature DB >> 6665749

Subacute massive pulmonary embolism treated with plasminogen and streptokinase.

D A Ellis, E Neville, R J Hall.   

Abstract

Major pulmonary embolism occurring insidiously over several weeks (subacute massive pulmonary embolism) has a high mortality and may not respond well to standard anticoagulant or thrombolytic treatment. A priming dose of plasminogen was used to enhance thrombolysis produced by a streptokinase infusion in five consecutive patients with subacute massive pulmonary embolism. In each patient a dramatic clinical improvement occurred with a substantial increase in pulmonary blood flow. All five patients survived to leave hospital. Malignant disease was the underlying cause of embolism in three patients, two of whom died of their malignant disease in the six months after treatment of their pulmonary embolism. The third patient with malignant disease had a choriocarcinoma; at least some of the pulmonary obstruction may have been tumour tissue but this obstruction was dramatically cleared by the treatment. The use of a combination of plasminogen with streptokinase should be considered in severely ill patients with subacute massive pulmonary embolism, particularly if other treatment, including streptokinase alone, has failed.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6665749      PMCID: PMC459694          DOI: 10.1136/thx.38.12.903

Source DB:  PubMed          Journal:  Thorax        ISSN: 0040-6376            Impact factor:   9.139


  7 in total

1.  Clinical course and late prognosis of treated subacute massive, acute minor, and chronic pulmonary thromboembolism.

Authors:  G C Sutton; R J Hall; I H Kerr
Journal:  Br Heart J       Date:  1977-10

2.  Comparison of streptokinase and heparin in treatment of isolated acute massive pulmonary embolism.

Authors:  G A Miller; G C Sutton; I H Kerr; R V Gibson; M Honey
Journal:  Br Med J       Date:  1971-06-19

3.  Plasminogen and moderate doses of urokinase in the treatment of acute pulmonary embolism.

Authors:  P Griguer; B Charbonnier; F Latour; J P Fauchier; M Brochier
Journal:  Angiology       Date:  1979-01       Impact factor: 3.619

4.  Treatment of deep-vein thrombosis with intermittent streptokinase and plasminogen infusion.

Authors:  V V Kakkar; S Sagar; M Lewis
Journal:  Lancet       Date:  1975-10-11       Impact factor: 79.321

5.  The plasminogen content of thrombi.

Authors:  D Ogston; C M Ogston; H W Fullerton
Journal:  Thromb Diath Haemorrh       Date:  1966-01-31

6.  Differences in the binding to fibrin of native plasminogen and plasminogen modified by proteolytic degradation. Influence of omega-aminocarboxylic acids.

Authors:  S Thorsen
Journal:  Biochim Biophys Acta       Date:  1975-05-30

7.  Subacute massive pulmonary embolism.

Authors:  R J Hall; D McHaffie; C Pusey; G C Sutton
Journal:  Br Heart J       Date:  1981-06
  7 in total
  3 in total

1.  Use of nebulised liposomal amphotericin B in the treatment of Aspergillus fumigatus empyema.

Authors:  I F Purcell; P A Corris
Journal:  Thorax       Date:  1995-12       Impact factor: 9.139

2.  Mechanical breakdown and thrombolysis in subacute massive pulmonary embolism: A prospective trial.

Authors:  Bishav Mohan; Shibba Takkar Chhabra; Naved Aslam; Gurpreet Singh Wander; Naresh Kumar Sood; Sumati Verma; Anil Kumar Mehra; Sarit Sharma
Journal:  World J Cardiol       Date:  2013-05-26

Review 3.  Role of extracorporeal membrane oxygenation and surgical embolectomy in acute pulmonary embolism.

Authors:  Marc de Perrot
Journal:  Curr Opin Pulm Med       Date:  2022-07-22       Impact factor: 2.868

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.